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By definition, tumours are heterogeneous. They are defined by marked differences in cells, microenvironmental factors
(oxygenation levels, pH, VEGF, VPF and TGF-a) metabolism, vasculature, structure and function that in turn translate into
heterogeneous drug delivery and therapeutic outcome. Ways to estimate quantitatively tumour heterogeneity can improve drug
discovery, treatment planning and therapeutic responses. It is therefore of paramount importance to have reliable and
reproducible biomarkers of cancerous lesions’ heterogeneity. During the past decade, the number of studies using histogram
approaches increased drastically with various magnetic resonance imaging (MRI) techniques (DCE-MRI, DWI, SWI etc.) although
information on tumour heterogeneity remains poorly exploited. This fact can be attributed to a poor knowledge of the available
metrics and of their specific meaning as well as to the lack of literature references to standardised histogram methods with which
surrogate markers of heterogeneity can be compared. This review highlights the current knowledge and critical advances needed
to investigate and quantify tumour heterogeneity. The key role of imaging techniques and in particular the key role of MRI for an
accurate investigation of tumour heterogeneity is reviewed with a particular emphasis on histogram approaches and derived
methods.
TUMOUR HETEROGENEITY: METHODS ARE NEEDED FOR
AN APPROPRIATE CHARACTERISATION
Investigating tumour heterogeneity is a key point in cancer
research because inter- and intra-tumour differences have so far
limited the development of targeted therapies for patients.
Heterogeneity in tumours already exists at the cell level and is
highly influenced by this cell’s genetic background and origin as
well as the environment where it establishes (De Sousa et al, 2013).
The wide varieties of genetic, cellular and molecular mutations that
may occur during the course of tumour development or as a
response to treatment are complex. Their characterisation becomes
even more difficult if these mutations occur in individual cancers
or in tumour subtypes. This has direct implications on the clinical
outcome as well as the development of adequate therapies. Intra-
tumour heterogeneity prevents an adequate clinical diagnosis and
is involved in tumour resistance. The identified existence of multiple
clones within a tumour orientates newer therapies towards more
personalised treatments including those targeting specific clone
subsets. Although appropriate indices of heterogeneity have already
shown to be good predictors of cancer progression, ways to
investigate and appreciate the extent of this heterogeneity are still
lacking due in part to a poor understanding of the molecular
mechanisms underlying it.
A better and more systematic appreciation of intra and inter-
tumour heterogeneity is crucial for drug development as well as for
the accurate assessment of response to treatment. In addition,
although combination therapies have proved their value, a better
understanding and quantification of tumour heterogeneity should
improve the design of therapeutic schemes (where and when a
drug must be introduced).
Finally, the speed of development of therapeutic agents will also
be increased, whereas costs will be drastically limited. These
improvements may be explained by the faster determination of the
different vascular and cellular components of a tumour based on
improved characterisation of heterogeneity and guided therapeutic
schemes. Targeted approaches such as personalised treatment aim
to produce greater effectiveness and less toxicity. Efforts are under
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way to target responder populations (e.g., aromatase inhibitors for
women that slowly metabolise tamoxifen and that may be at
increased risk of cancer progression) rather than assuming that all
the patients can receive treatments to the same extent. Thus, a
better characterisation of cancer biology with non-invasive
methods in conjunction with an enhanced knowledge of the
molecular, metabolic and genomic profile of tumours and their
subsets helps the understanding of the tumour environment and
the development of new clinically relevant biomarkers. These can
identify drug sensitivity for a faster enrolment of candidates who
will benefit from a treatment under study. As a consequence, the
cost-effectiveness of targeted drugs should be demonstrated.
Moreover, faster decisions will be taken on whether to continue
or stop drug development avoiding at the same time further
exposure of experimental animals and patients and further costs.
The evaluation of tumour heterogeneity improved tremendously
with the advent of imaging techniques such as optical imaging
techniques, positron emission tomography and magnetic reso-
nance imaging (MRI) both at the clinical and experimental levels.
The combination of these imaging modalities can provide greater
insights into characterisation of tumour heterogeneity: cancers
display various kinds of heterogeneity such as cellular morphology,
gene expression, metabolism, angiogenic and proliferative potential
that can be specifically investigated using optical imaging or
positron emission tomography for molecular and metabolic
imaging and MRI for investigating angiogenic processes (DCE-
MRI) and cellular morphology (diffusion). Here, we focus on MRI
techniques.
The strength of MRI compared with other imaging modalities
(CT, positron emission tomography) resides in its potential
to provide a vast array of different image contrasts (T1, T2,
diffusion-weighted, flow-weighted, magnetisation transfer,
chemical exchange saturation transfer, etc.) at a high spatial
resolution, in a three dimensional manner and non-invasively
providing unique insight into tumour heterogeneity. Various
physiological parameters have been estimated on a voxel by voxel
basis allowing a full visualisation of the tumour heterogeneity
during its progression or during its regression following a
treatment. However, in many studies, average parameters over
entire regions of interest are calculated and compared. The
methodologies for calculating and interpreting voxel by
voxel values are poorly known and may be time-consuming.
Unfortunately, mean and median quantitative values are not
always significantly sensitive to small changes or treatment effects.
In addition, they may not represent the precise status of the
tumour owing to the intrinsic chaotic environment of tumours,
which may be drastically different between tumours of the same
type or within tumours where one part may be viable and the other
not. With increasing advances in both high-resolution MRI and
signal processing methods, histogram analysis of cancer MRI is
more and more used. This methodology showed its usefulness for
investigating the distributions of various tumour parameters such
as permeability in dynamic contrast-enhanced MRI (DCE-MRI)
(Hayes et al, 2002; Padhani, 2002; Peng et al, 2012), vessel size
index and blood volumes (VSI, CBV) (Just, 2011; Burrell et al,
2012) and apparent diffusion coefficient (ADC) in diffusion MRI
(Downey et al, 2013).
Principles of first-order histogram analysis, parameters. The
histogram of an image is a function showing (for each intensity
level) the number of pixels in the whole image having the same
intensity. It describes in a simple manner the statistical information
contained in the image. Most histogram analyses use descriptive
parameters to characterise and compare distributions of tumour
biomarkers in a quantitative manner. A descriptive analysis reports
the following quantitative factors: mean, standard deviation, mode,
maximum and minimum, kurtosis, skewness, and percentiles as
well as entropy. These parameters represent the first-order
statistical properties of the image. Mean and standard deviations
represent average and dispersion of the histogram, respectively.
The mode represents the value with highest counts. Kurtosis,
skewness and entropy are usually more difficult to apprehend and
interpret. Kurtosis reflects the peakedness of the distribution and is
a measure of the shape of the probability distribution (Figure 1).
Skewness represents a measure of asymmetry of the probability
distribution. The entropy represents a statistical measure of the
‘irregularities’ in a histogram. Entropy is a recognised parameter
allowing describing the variation of a parameter of interest’s
distribution. Finally, a percentile represents the value below which
a percentage of observations is calculated. Apart from these
statistical and mathematical considerations, the meaning of these
metrics in cancer studies is ambiguous (Figure 1). Although many
studies agree that histogram analyses add information for
discriminating between benign and malignant regions (Carter
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Figure 1. Interpretation of the properties of histograms. (A). Definition
of mean, median and percentiles. P25¼ 25th percentile; P75¼75th
percentile. (B). Kurtosis (K) Platykurtosis indicates a flatter peak with
negative kurtosis (left, Ko0), and leptokurtosis indicates a sharp peak
with positive kurtosis (Right, K40). Skewness: if a histogram has an
elongated tail on the left side of the mean, it is negatively skewed. If a
histogram has an elongated tail on the right side of the mean, it is
positively skewed.
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et al, 2013) or for a better characterisation of response to
treatment, very few of them try to interpret the true meaning of
kurtosis, skewness and percentile parameters.
Until recently, a majority of clinical studies using histograms
were performed in the brain (see Table 1) less contaminated by
motion. Nevertheless, histograms are more and more used in extra-
cranial areas such as endometrial cancer (Woo et al, 2013), renal
cell cancer (Chandarana et al, 2012), and cervical and breast cancer
(Johansen et al, 2009; Yuh et al, 2009). In Table 1, a list of recent
studies is provided, showing that histogram factors can be
significant predictors of response to treatment in various types of
clinical and experimental cancers (King et al, 2013). Mean, median
and percentiles are the histogram parameters mostly investigated
although skewness and kurtosis were evaluated more often recently
(Baek et al, 2012; Chandarana et al, 2012; Downey et al, 2013;
King et al, 2013). Entropy has not been widely used to date but the
increased investigation of cancers with texture analysis, which can
be seen as a second order histogram analysis methodology, should
certainly change this (Foroutan et al, 2013). The majority of studies
have investigated distributions of ADC, CBV and DCE-MRI
parameters such as Ktrans or extravascular extracellular space (EES)
although various other DCE-MRI characteristics such as lesion
enhancement, wash in slope or area under the curve have been
investigated with histograms (Table 1).
Histogram analysis has mostly been performed on data collected
from manually drawn regions of interest (ROI) (Baek et al, 2012;
Foroutan et al, 2013; King et al, 2013; Song et al, 2013; Woo et al,
2013). Although ROIs were drawn by trained observers and/or
radiologists in clinical studies, ROI-based methods include
interobserver variability in ROI positioning and misregistration
between pre- and post-contrast-enhanced images that can create
confounds in histograms. As an alternative, Chandarana et al
(2012) proposed the use of a segmentation algorithm on
preregistered pre- and post-contrast images of renal cell cancer
(RCC) subtypes. The assessment of whole lesion enhancement
descriptive histogram parameters using semi-automated programs
showed significant increases in sensitivity, specificity and accuracy
in the diagnosis of RCC compared with ROI analysis.
Kurtosis, skewness and percentiles as biomarkers of tumour
heterogeneity. Kurtosis, skewness and percentiles appear to be
promising parameters for differentiating between different types of
gliomas (Just, 2011), between pseudoprogression and early tumour
progression in glioblastomas (Baek et al, 2012; Song et al, 2013)
and between cancer subtypes (Chandarana et al, 2012). Percentiles,
kurtosis and skewness of ADC distributions were correlated to
histological grade with statistical tests and allowed grading of
endometrial cancer (Woo et al, 2013) and differentiation between
cervical cancers (Downey et al, 2013). Baek et al (2012) examined
the predictive value of percentiles, skewness and kurtosis for
discrimination between pseudoprogression and progression of
glioblastomas. Patients with newly diagnosed glioblastomas that
developed enlarged contrast-enhanced lesions after chemotherapy
and radiation therapy following surgical resection underwent
perfusion MRI. A classification of the percent change in skewness
and kurtosis of the normalised cerebral blood volume (nCBV)
during the early treatment period was performed allowing the
characterisation of predictors of tumour regression by means of a
multivariable logistic regression analysis. Patients were categorised
into two groups: those with early tumour progression and those
with pseudoprogression both confirmed by pathologic analysis.
Visual analysis of histographic patterns of nCBV histograms
demonstrated that post- chemotherapy and radiation therapy
contrast-enhanced lesions classified as pseudoprogression had
positive changes in kurtosis and skewness and lower range, mode
and maximum than lesions classified as early tumour progression.
In pseudoprogression, lesions demonstrated positive changes in
kurtosis and skewness as well as leptokurtosis whereas negative
changes in kurtosis and skewness and platykurtosis were found in
early tumour progression. Furthermore, regression and receiver
operating characteristic analyses demonstrated significant associa-
tions of histographic patterns with early tumour progression. Song
et al (2013) completed this study using the same methodology to
differentiate true progression from pseudoprogression using
histogram analysis of ADC. The 5th percentile of the cumulative
histogram analysis was the only independently differentiating
variable in the multivariate analysis.
Histogram parameters (mean, median, 75th percentile) were
significantly higher in clear cell RCC (ccRCC) than in the papillary
subtype of RCC (pRCC) (Chandarana et al, 2012). However,
kurtosis and skewness were significantly lower in ccRCC. In
addition, an accurate choice of cutoff values for histogram-
descriptive parameters drastically increased the accuracy, specifi-
city and sensitivity of the discrimination of ccRCC from p. Finally,
kurtosis had the best interreader agreement in discriminating
ccRCC from pRCC. As mentioned by the authors, their study was
limited by ‘a` priori’ knowledge of lesion classification and by the
needs to extend to other less occurring RCC subtypes to
demonstrate its true value.
Histogram approaches also showed their added value as
predictors of response to treatment in various clinical and pre-
clinical cancers (Chang et al, 2004; Johansen et al, 2009; Peng et al,
2012; Shukla-Dave et al, 2012; Foroutan et al, 2013; King et al,
2013; Mignion et al, 2014). Skewness and kurtosis of ADC and
Ktrans distributions were used as predictors of treatment response
in head and neck squamous cell carcinoma (HNSCC) (Shukla-
Dave et al, 2012; King et al, 2013). King et al (2013) examined the
value of diffusion-weighted imaging (DWI) for the prediction of
treatment failure in primary stage III and IV HNSCC. Histogram
analysis of ADC in pre- and post-radiation therapy was able to
predict local failure within 2 years of treatment. Strong and
significant trends for higher mean ADC and ADC skewness and
kurtosis were identified in HNSCC tumours that failed treatment.
Shukla-Dave et al (2012), on the other hand, wanted to assess the
potential of DCE-MRI as a prognostic value of pre-treatment
(surgery or chemoradiation therapy) in HNSCC patients and
found that skewness of Ktrans was a strong predictor of
progression-free survival and overall survival in HNSCC patients
with stage IV nodal disease. Histogram approaches and in
particular, skewness and kurtosis parameters demonstrated their
added value when investigating the same cancer type with different
MRI techniques. Histogram analysis of HNSCC lesions allowed
prediction of patient outcome pre- and post treatment using DCE-
MRI and DWI, respectively. Changes in the asymmetry of ADC
and Ktrans distributions may reveal different structural and
functional characteristics of HNSCC lesions before and after
treatment. These tumours are generally characterised by hetero-
geneous regions of hypoxia and necrosis contributing to poor
treatment response because of resistance to radiation therapy.
Hypoxic regions are generally less perfused within tumours and
have shown increased asymmetric distributions (skewness) of
transfer constants (Ktrans, Kep) in DCE-MRI, indicating poor
perfusion. Tumour necrotic areas may have higher ADC values
than in non-necrotic areas. Therefore, high ADC may be predictive
of a poor treatment response. In primary HNSCC lesions, higher
ADC skewness and kurtosis and a small increase of the percentage
change of mean ADC showed local failure of an early radiation
therapy treatment indicative of intratumoural low oxygen tensions.
Histogram analysis of HNSCC not only provided predictors of
patient outcome but also was able to inform regarding the tumour
environment. This may be useful to identify patients requiring a
transition to a more aggressive treatment or combination of
treatments or even surgery. In both studies of HNSCC, statistical
analysis of histogram parameters was performed using univariate
Histogram analysis in cancer magnetic resonance imaging BRITISH JOURNAL OF CANCER
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Table 1. Fundamental and clinical studies using histogram analysis
Study
Clinical/
experimental Cancer Parameter Histogram analysis P-value Features
Baek et al, 2012 Human Glioblastoma CBV Skewness 0.02 Testing the predictive value of skewness
and kurtosis
Kurtosis 0.035 Differentiating early tumour progression
from pseudoprogression
Histographic pattern 0.002
Range 0.002
Mode 0.005
Song et al, 2013 Human Glioblastoma ADC 5th percentile 0.009 True progression vs pseudoprogression
CBV 95th percentile 0.015 True progression vs pseudoprogression
Just, 2011 Rat Gliomas VSI, CBV 25th percentile, 75th
percentile
o0.023 VSI and BV of human and rodent gliomas
Peng et al, 2012 Human Brain tumours Wash in
slope
mFWHM o0.001 Evaluation of tumour brain response to
radiotherapy
Tozer et al, 2007 Human Low-grade gliomas:
oligodendroglioma,
oligoastrocytoma
ADC PH; PL; mean value;
10th, 25th, 50th, 75th
and 90th, skewness
To investigate whether low-grade
astrocytomas and oligodendrogliomas
exhibit different ADC histogram
characteristics because of their biological
difference and whether diagnoses of
tumour subtype can be suggested at
presentation using the histogram alone
Kim et al, 2013 Human Low-grade gliomas
vs high-grade
gliomas
CBV 99th percentile o0.001 To retrospectively assess the usefulness of a
cumulative CBV histogram for grading
gliomas
Mean 0.014
Nowosielski et al, 2011 Human Recurrent high-
grade glioma
ADC To evaluate ADC maps to distinguish anti-
vascular and anti-tumour effects in the
course of anti-angiogenic treatment of
rHGG
Change in skewness P¼ 0.04
Rodriguez Gutierrez
et al, 2014
Human Paediatric posterior
fossa tumours
ADC Skewness, kurtosis mode
10%, 25%, 50%, 75%
and 90% energy,
entropy, mean variance,
texture analysis and
parameters
Improving current posterior fossa
discrimination of histological tumour type
Chandarana et al, 2012 Human Renal cell cancer Lesion
enhancement
Mean o0.001 Discriminating ccRCC from pRCC
Median o0.001
75th percentile o0.001
Kurtosis o0.001
Skewness o0.001
Woo et al, 2013 Human Endometrial cancer ADC 25th, 75th, 90th, 95th
between grades
o0.03 Histogram analysis of endometrial cancer
ADC provides potential parameters for
grading preoperative tumours
25th, 75th, 90th, 95th o0.024
Shukla-Dave et al, 2012 Human HNSCC Ktrans Skewness o0.001 Assessment of the value of DCE-MRI in
HNSCC patients with nodal disease
undergoing chemotherapy
King et al, 2013 Human HNSCC ADC Mean 0.112 Prediction of treatment failure in HNSCC
Kurtosis 0.04
Skewness 0.015
Crokart et al, 2005 Mice Liver tumours,
fibrosarcomas
Ktrans, Kep,
vp
Mean histographic
patterns
o0.05 Explore anti-inflammatory drugs for
radiosensitisation of tumours
Johansen et al, 2009 Human Advanced breast
cancer
Relative SI,
AUC (DCE-
MRI)
Mean and 10th
percentile
0.02 Early prediction of response to neoadjuvant
therapy
Kyriasi et al, 2011 Human Metastatic ovarian
cancer
ADC Mean, 10th, 25th, 50th,
75th, 90th
o0.001 Evaluation of ADC histograms for predicting
chemotherapy response. Significance was
reached after the third course
Primary peritoneal
cancer
Kurtosis, skewness o0.006
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as well as multivariate logistic regression analyses to assess the
statistical significance of the combinations of prognostic variables
(Shukla-Dave et al, 2012) or to predict outcome and time to
recurrence (King et al, 2013). Almost all the clinical studies
presented in this review used univariate and multivariate statistical
analyses to statistically correlate the value of either DCE-MRI
parameters or DWI parameters with survival, age or sex. Most of
these studies also included receiver operating characteristic
analyses allowing the identification of the optimal threshold of
any significant histogram parameter as well as maximisation of
accuracy, sensitivity and specificity. These statistical evaluations are
usually absent from preclinical cancer studies (Just, 2011; Foroutan
et al, 2013; Mignion et al, 2014), but should definitely be
investigated in preclinical models where histogram parameters
could be used to evaluate their translational value to the clinics.
King et al (2013) stated that the appropriate definition of ADC
threshold is of clinical interest and in HNSCC lesions, knowledge
of the high positive skewness and kurtosis and their thresholds
altogether were predictive of treatment failure.
Thus, changes in histogram shape and asymmetry reflect
microstructural and functional differences in tumour composition
that might be of relevant interest for the development of
therapeutic strategies in cancer. These parameters could also
represent a step forward to considering MRI as a non-invasive
‘histological’ method (Just, 2011; Friedman et al, 2012). In this
regard, preclinical studies have the advantage of providing
histological evaluation more often than clinical studies that are
biopsy-dependent. Foroutan et al (2013) examined the ADC
properties of sarcomas in mice upon treatment combination of
MK1775 and gemcitabine across several days. ADC increased
significantly and durably because of the combined treatment. ADC
distributions demonstrated marked asymmetric patterns and a
broader peak. At 24 h post treatment, negative skewness and
kurtosis were demonstrated, whereas control groups showed
positive increases. Histological measures showed a trend towards
correlation of treatment response with decreased cellularity and
further analysis with cleaved caspase 3 antibody staining confirmed
the increased presence of apoptotic structures in tumour sections.
Thus, the significant and rapid increases in ADC distribution
confirm that ADC is a predictive marker of acute cytotoxic effects
due to increased apoptosis that allow for more unrestricted
diffusion.
CURRENT TECHNIQUES INVESTIGATING TUMOUR
HETEROGENITY WITH HISTOGRAMS
One of the main goals of the present review is to explain the
specific meaning of histogram metrics and relate them to more
physiological concepts for an improved consideration of these
parameters as surrogate markers of tumour heterogeneity. Some of
the most used techniques for the assessment of tumour features
and tumour response to treatment such as DCE-MRI, diffusion-
weighted MRI (DWI) as well as susceptibility-weighted MRI are
reviewed in conjunction with histogram methods. For a better
interpretation of histogram parameters, Table 2 summarises the
overall trends emanating from recent DCE-MRI, DWI and
susceptibility-weighted imaging studies.
Dynamic contrast-enhanced MRI. In 2002, Hayes et al (2002)
compared for the first time, distributions of transfer constants
(Ktrans) in responder and non-responder patients to various
treatments. Since then, the number of studies using histogram-
based analysis increased drastically to address the heterogeneity of
various tumour biomarkers pre- and post treatment. Indeed, the
development of histogram-based analyses needed strong improve-
ments in MRI techniques as well as modelling techniques. With
increased spatial and temporal resolutions as well as improvements
Table 1. ( Continued )
Study
Clinical/
experimental Cancer Parameter Histogram analysis P-value Features
Chang et al, 2004 Human Breast cancer Amplitude Mean, s.d., kurtosis,
skewness
o0.05 Angiogenic response to neoadjuvant
chemotherapy
Kout Before, after first and after final
chemotherapy
Peak
enhancement
Yuh et al, 2009 Human Cervical cancer Tumour
volume
2.5th to 20th percentile o0.008 Predictive power of MRI perfusion
parameters
Signal
intensity
During early treatment
Downey et al, 2013 Human Cervical cancer ADC 10th, 25th, 50th, 70th,
90th percentiles
o0.05 Differentiation of cervical tumours
according to their histological
characteristics
Skewness, kurtosis 0.016
Foroutan et al, 2013 Mice Sarcoma ADC % change in mean ADC o0.007
(D2)
Evaluation of the combination of
gemcitabine and MK1775 treatment at
early time points
Skewness 0.018
Kurtosis 0.043
Entropy 40.05
0.023
(Gems
only or
MK1775
only)
Abbreviations: ADC¼ apparent diffusion coefficient; AUC¼ area under the curve; ccRCC¼ clear cell renal cell cancer; CBV¼ cerebral blood volume; D2¼day 2; DCE-MRI¼dynamic contrast-
enhanced magnetic resonance imaging; HNSCC¼ head and neck squamous cell carcinoma; mFWHM¼modified full width at half maximum; PH¼peak height; PL¼peak location;
pRCC¼papillary subtype of renal cell cancer; rHGG¼ recurrent high-grade gliomas; VSI¼ vessel size index.
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in signal to noise ratios and anatomical coverage, advances in
alternative methods of data analysis such as histogram approaches
were made possible allowing progress in the assessment of changes
in tumour heterogeneity. The value of histograms was demon-
strated in many early DCE-MRI studies where simple pooling of
pharmacokinetic model voxel-fitted parameters and appropriate
definition of thresholds revealed important spatial information in
anti-angiogenic-treated tumour models and clinical studies (Chang
et al, 2004; Li et al, 2005). Histogram analyses appeared to be
particularly sensitive to changes in heterogeneity due to treatments.
In this context, histograms of surrogate markers of permeability
(Ktrans) and the fractional volume of EES became a very important
tool allowing the assessment of the angiogenic compositions of the
whole tumour. The distributions of Ktrans values allowed spatial
discrimination of responses to treatment essentially between the
rim and core of tumours. In solid tumours, the core is often
hypoxic and/or necrotic and grows slowly compared with the
highly vascularised rim. These characteristics define the aggres-
siveness and growth patterns of tumours and have critical
implications for improved treatments. The accessibility of drugs
to the tumour core is made difficult and few ways to visualise and
evaluate the drug penetration are available. In many pre-clinical
studies, the histographic patterns showed transformation from a
broad and heterogeneous Ktrans distribution to a narrow one upon
anti-angiogenic treatments (Crockart et al, 2005; Jordan et al,
2005). As reported in Table 2, tumour progression appears to be
linked to skewed parameter (Ktrans, Kep, wash in slope) distribu-
tions with long tails, expansion of histograms to the right
(Increased permeability) as well as peak broadening with decreased
height (Chang et al, 2004; Peng et al, 2012). All non-responders to
radiotherapy in brain tumour patients demonstrated broadened
histograms of the wash in slope in line with increased tumour size,
whereas responders showed narrowed histogram and decreased
tumour sizes (Peng et al, 2012). Histographic patterns of DCE-MRI
factors after anti-angiogenic or anti-vascular treatment demon-
strated skewed distributions to the left with narrower peak and
increased height (Table 2). Parametric histograms were also used to
characterise breast cancer heterogeneity by correlation of histo-
grams to tumour response in a longitudinal manner during
neoadjuvant chemotherapy (Chang et al, 2004). The usefulness of
DCE-MRI of breast tumours for characterising tumour angiogen-
esis, multifocal lesions or residuals as well as allowing reliable
discrimination between benign and malignant lesions as well as
assessment of treatment response has been widely demonstrated.
Compared with many DCE-MRI studies that use an average signal-
time course or concentration-time course to assess tumour
responses, Chang et al (2004) analysed the tumour composition
using histograms as a function of time during neoadjuvant therapy.
A better response was associated to a larger change from
heterogeneous to homogeneous distributions of amplitude with
progressive increases in kurtosis and decreases in standard
deviations and mean during chemotherapy. The composition of
breast tumours with the highest amplitudes was the most
susceptible to chemotherapy. These features may be helpful in
future studies for understanding pathophysiological changes and
for guiding therapeutic approaches. To date, metrics such as
kurtosis, skewness and percentiles were less used in DCE-MRI
clinical studies, although these parameters were predictive of
radiological outcome (Chang et al, 2004) and provided improved
diagnostics. DCE-MRI usually explains the kinetics of Gd-DTPA
uptake within tumours using pharmacokinetic compartment
modelling. Concentration-time curves are fitted to the model and
estimates of permeability, tumour vessel flow, blood volume and
fractional volume of EES are usually obtained (Leach et al, 2005).
However, features of signal intensity-time curves can also be
analysed such as gradient, overall shape, time to maximum
enhancement, wash in slope and wash out that are usually more
sensitive to individual variations. The initial area under the
contrast-agent concentration-time curve representing a combina-
tion flow, blood volume and vessel permeability is also often used.
All these model-free parameters appear to have more sensitive
histogram distributions to underlying changes in the tumour
environment than model-dependent parameters (Ktrans, EES, vp)
that have contributions from the arterial input function, the ability
of the model to fit the data and remain ‘indirect’ surrogate markers
unlike ADC or CBV (discussed below) that are more directly
linked to tumour structural changes.
Diffusion MRI. During the past 10 years, DWI and diffusion
tensor imaging methods have generated an increased interest for
the entire MR community. In oncology, biomarkers estimated
from DWI have been related to tumour aggressiveness and tumour
response. Part of this interest is also because of the use of
histogram approaches as they provide a quantitative methodology
to analyse visible and invisible changes in tumour data in a
reproducible manner (Downey et al, 2013). However, the success
of diffusion techniques in turn highly contributed to the
development of histogram analysis strategies. Nowadays, most
studies report histogram investigations of either apparent diffusion
coefficient (ADC) or fractional anisotropy in tumours (King et al;
2013; Song et al, 2013; Woo et al; 2013). Histograms are even
considered to be a prerequisite in most DWI studies (Padhani et al,
2009; Ahn et al, 2012; Rosenkrantz, 2013). Histogram approaches
are particularly adapted to evaluate tumour heterogeneity as they
can pick up different microenvironments that may be masked by
mean ADC values. ADC measures the Brownian motion of water
Table 2. General histogram trends in DCE-MRI, DWI-MRI, perfusion MRI and VSI-MRI studies during tumour progression and
upon treatment
Techniques Tumour progression Treatment
DCE-MRI Skewed distributions with long tails Anti-angiogenic treatment, cytostatic treatment: histograms reduced to the left with
narrower, normal peak and increased height
Expansion of histograms to the right Anti-vascular treatment: skewed histograms with increased peak height to the left
Peak broadening with decreased height
DWI (ADC) Sharp histogram with high skewness and kurtosis
and elevated peak height
Shift to the right side as mean ADC is increased and flatter or broader ADC histograms
with decreased skewness and kurtosis (King et al, 2013; Song et al, 2013)
Perfusion,
DSC-MRI (CBV)
Decreased skewness, flat CBV histograms Increased skewness and sharp histogram (Baek et al, 2012)
VSI-MRI Increased skewness to the right side of histograms,
increased height of peaks on the left side
Anti-vascular treatment: decrease of 25th percentile (Burrel et al, 2012), increased
kurtosis
Abbreviations: ADC¼ apparent diffusion coefficient; CBV¼ cerebral blood volume; DCE-MRI¼dynamic contrast enhanced magnetic resonance imaging; DSC-MRI¼dynamic susceptibility
enhanced magnetic resonance imaging; DWI-MRI¼diffusion-weighted magnetic resonance imaging; VSI-MRI¼ vessel size index magnetic resonance imaging.
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molecules. In solid cancers, low ADC values correspond to
restricted diffusion. In post-treatment cancers, ADC values are
increased because of cell death and reduction of restrictive barriers
but foci of necrosis may also display high ADC values. Necrotic
areas are often associated to hypoxic areas resistant to radiotherapy
and therefore indicating poor treatment outcome. On the other
hand, increased ADC may also be due to increased interstitial
osmolality and apoptosis. Anti-VEGF therapies may as well lead to
reduced ADC values as a consequence of decreased interstitial
osmolality and reduced vasogenic oedema. Histograms of ADC
alone were able to identify astrocytomas from oligodendrogliomas,
two glioma subtypes, by statistical comparisons of mean, mode,
peak height, percentiles and skewness and by operating a
classification of glioma subtypes using a discriminant analysis of
each histogram parameter (Tozer et al, 2007). Again, changes in
diffusivity patterns could be matched to histopathological patterns
and were linked to differences in cell density. Differentiation of
benign from malignant cervix tumours was possible by evaluating
percentiles as well as skewness and kurtosis of ADC distributions
from manually drawn ROIs around cervical tumours (Downey
et al, 2013; Rosenkrantz, 2013). A significant difference was found
between squamous cell carcinomas and adenocarcinomas in terms
of skewness that supposedly reflects a more heterogeneous
architecture of adenocarcinomas, but not with percentiles and
kurtosis. The significant median ADC was able to differentiate
between tumour grades. In addition, the skewness and kurtosis of
ADC histograms predicted response to angiogenic therapy
(bevacizumab/irinotecan) in recurrent high-grade gliomas showing
that patients with increased skewness had a shorter progression-
free survival compared with patients with stable or decreased
skewness (Nowosielski et al, 2011). Identification of early response
in patients with newly diagnosed or recurrent ovarian cancer was
possible demonstrating significantly decreased skewness and
kurtosis after a third cycle of therapy (Kyriasi et al, 2011). These
general histographic patterns are summarised in Table 2 for
tumour progression and treatment responses and show reprodu-
cibility in a wide variety of cancers and treatments. To ensure
adequate histogram distributions of ADC, efforts have to be made
at the acquisition level with proper choice of b values (Downey
et al, 2013) and in the map segmentation to avoid contamination
from CSF known to induce potential confounds. Most of the
aforementioned studies provide a potential alternative to histology
avoiding randomly sampled specimens and patient discomfort.
Susceptibility-weighted MRI methods: Dynamic susceptibility
contrast MRI, vessel size index MRI and blood oxygen level-
dependent MRI. Susceptibility-weighted MRI methods also bene-
fited from the development of histogram-based techniques. As
mentioned earlier, the chaotic development of tumour vasculature
induces vascular heterogeneities in blood flow, blood volume,
vessel diameters, delays and dispersion that can be investigated
with DSC-MRI, VSI MRI or arterial spin labelling techniques.
Cumulative histogram analysis of CBV with accurate choice of
cutoff values not only allowed discrimination between low- and
high-grade gliomas but also between grade IV and grade III
gliomas with an increased diagnosis accuracy (Kim et al, 2013).
CBV maps were obtained from DSC-MRI acquisitions at 3T in
patients with astrocytic tumours. Significant differences between
low- and high-grade gliomas and between grade III and grade IV
gliomas were obtained for the 99th percentile of the cumulative
normalised CBV histograms, the mean and peak height.
Several recent histogram analyses of DSC-MRI and arterial spin
labelling data demonstrated the usefulness and power of
descriptive histogram parameters of CBV for discriminating
between pseudoprogression and progression in glioblastomas
(Baek et al, 2012; Choi et al, 2013; Song et al, 2013) pointing to
a more recurrent use of this type of analysis in the future. However,
the added value of histogram analyses can definitely be observed
in studies where correlations between susceptibility-weighted
MRI data and histopathological characteristics can be explored.
VSI MRI and BOLD contrast MRI methodologies in rodents are
particularly sensitive to structural and/or physiological factors,
vessel radius and oxygenation levels for instance. Histograms of
these parameters showed to be effective biomarkers of tumour
heterogeneity changes (Robinson et al, 2003; Just, 2011; Burrell
et al, 2012). In addition, results of histogram analysis of VSI
response to anti-vascular therapy were reproducible across studies
(decrease of the 25th percentile of vessel diameter) (Howe et al,
2008) and demonstrated different histographic patterns in
response to treatment. Skewness, kurtosis and percentiles of the
VSI and fBV distributions in different types of experimental
gliomas showed significant differences between gliomas of murine
origin but not between gliomas of human origin (Just, 2011)
revealing the capacity of these parameters to expose microregional
differences that could be of importance for providing character-
istics on the tumour angiogenic phenotype. General histographic
patterns for DSC-MRI and VSI-MRI are summarised in Table 2.
INTRODUCTION TO OTHER TECHNIQUES FOR
EVALUATING TUMOUR HETEROGENEITY
One of the major pitfalls of histogram analysis is the poor
correspondence with the spatial organisation of tumours although
threshold values can be defined to correspond to parameter of
interest mapping. In addition, performing statistics on distribu-
tions is not straightforward and can lead to large errors (Rose et al,
2014). Other approaches derived from histogram analysis have
thus been developed. Amongst the most used are texture analysis
and Re´niy fractals. These techniques are often called second-order
histogram analyses and take into account the joint probability
distributions of pairs of pixels using parameters such as energy,
entropy, correlation to evaluate the uniformity, homogeneity,
internal arrangement and directionality of an image (or parameter
map).
Texture analysis identifies several similar patterns in an image
and groups them. In cancer MRI, it could be described as a ‘2D-
histogram’ or co-occurrence matrix analysis (Rose et al, 2009)
where the spatial information is necessary to differentiate tumour
voxels with similar histograms. Rodriguez Gutierrez et al (2014)
and Eliat et al (2012) were able to improve the classification of
paediatric posterior fossa tumours and subtypes and differentiate
between glioblastomas and malignant glioneuronal tumours,
respectively, on the basis of a combination of first- and second-
order histogram features demonstrating improved specificity and
sensitivity for differentiating tumours. These studies emphasised
the usefulness of texture-based classification techniques in
identifying tumour subtypes. In particular, optimisation of texture
analysis may help discrimination between genetic tumour subtypes
(Rodriguez Gutierrez et al, 2014 and references therein) in
agreement with improvements of patient comfort concepts
encouraging the development of noninvasive cancer classification.
Fractal dimensions (Rose et al, 2009) have also been used to add
knowledge of spatial arrangement in tumours to usual DCE-MRI
parameter distributions allowing to describe ‘heterogeneity bio-
markers’. Fractal dimensions are model-based tools for texture
analysis describing objects that have a high degree of irregularity.
Rose et al (2009) used fractal dimensions as well as geometrical
measurements to quantify random variations in DCE-MRI
parameter maps of low- and high-grade gliomas. Their methodol-
ogy comparing spatial heterogeneity statistics (information dimen-
sion, extruded surface area, etc.) for Ktrans and EES parameters
showed increased statistical difference (Po0.00005) for discrimi-
nating low-grade gliomas from high-grade gliomas compared with
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more conventional statistics (median and standard deviation)
(Po0.05).
Finally Rose et al (2014) also addressed the fundamental
problem of statistical significance of parametric tumour maps
using indexed distribution analysis of bevacizumab DCE-MRI data.
Compared with conventional and histogram analyses, indexed
distribution analysis was sensitive to heterogeneous changes and
spatial extent of bevacizumab treatment, even allowing inference
about treatment-induced decrease in Ktrans independence on
baseline values.
However, all these new methodologies require further validation
and are still based on previous evaluations of parameter
distributions. The validation of these biomarkers will require the
development of simple standardised methodologies across centres
and the creation of databanks including cancer types and subtypes,
treatments and parameters. One of the main pitfalls of histogram
and histogram-derived approaches concerns the retrospective
nature of most of the studies where histopathological features of
tumours are known and can bias the true usefulness of these novel
approaches. Another main limitation appears to be the low number
of patients bearing a specific type of cancer. Repeated and
reproducible trends need to be extracted from histogram factors
(such as kurtosis and skewness changes, for example) to become
key points for appropriate therapeutic decisions (Table 2).
CONCLUSION AND FUTURE CHALLENGES
For the past 15–20 years, advances in cancer characterisation and
assessment of response to treatment have been correlated to
advances in cancer imaging techniques. A vast majority of studies
have focused on the assessment of surrogate biomarkers of various
parameters (permeability (Ktrans), blood flow, diffusivity (ADC),
vessel diameter (VSI), etc.) allowing either grading of tumours,
discrimination between tumour types, benign or malignant lesions
or assessment of early response to treatment following anti-
angiogenic/anti-vascular or on the contrary progression of cancer,
metastatic outcome or patient outcome. Lately, progress in genetic,
cellular and molecular technologies allowed addressing tumour
heterogeneity in a more comprehensive manner with deepened
knowledge of genetic mutations of tumours and their subtypes.
These studies have generated a lot of interest as the increased
understanding of tumour heterogeneous environment is directly
implicated in the development of novel targeted therapies, their
combination and their clinical therapeutic schemes as well as the
interpretation of tumour resistance to therapy. In imaging-based
oncology research, although parametric voxel-by-voxel maps have
been used for a long time allowing visualisation of heterogeneity,
parameters have often been summarised into average or median
scalars that described only discrete aspects of the distributions of
parameters across tumours and were not even reflecting the
underlying biology. Descriptive first-order histogram approaches
remain simple and accessible to many investigators. Recently, a
wide range of clinical and pre-clinical studies have demonstrated
the potential of these analyses for grading, differentiating, assessing
progression and tumour responses. Increased specificity, sensitivity
and accuracy of histogram parameters have often been shown
compared with conventional or histopathological analyses. Metrics
such as kurtosis, skewness, percentiles and their changes demon-
strated to be strong and reliable quantitative surrogate markers of
tumour heterogeneity with a more direct correlation to the
underlying structural, physiological, molecular as well as metabolic
changes occurring upon tumour progression with and without
therapy. Texture analysis and fractals further improve quantitative
histogram approaches by introducing the spatial dimension
allowing better classification or grading. These later methodologies
are computer-demanding and need further validations although
they should provide high-quality diagnosis of tumour subtypes.
Critical challenges for the future involve validation and standardi-
sation of quantitative histogram approaches in large patient
populations as a reliable tool to characterise and classify tumour
heterogeneity non-invasively.
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